

**Press Release**

**Source: MBC Pharma Inc.**

## **MBC PHARMA INC. ANNOUNCES ISSUANCE OF KEY PATENT**

Aurora, CO – October 7, 2009 - MBC Pharma Inc., a privately held biopharmaceutical company announced today, that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,598,246 entitled " Bisphosphonate conjugates and methods of making and using the same ," on the bone targeting anticancer conjugates and method of delivering anticancer drugs to the bone and surrounding tissues. The patent includes coverage of any anticancer drug connected to a wide range of clinically approved bisphosphonates using MBC technology.

"The issuance of this patent expands our intellectual property estate for bone targeted therapeutics for treatment Cancer Induced Bone Disease as well as primary bone cancer and provides us with a broad coverage that applies well beyond nucleoside antimetabolites," said Alexander Karpeisky, President and CSO of MBC Pharma.

"Emerging evidence is driving a paradigm shift in the view of the bone as both a sanctuary for metastatic cancer cells, and the source of tumor recruited cells that support growth of bone and non-bone metastases. MBC's bone targeting platform, now a patent protected position, is ready for this paradigm shift and clearly on the cutting edge of oncology drug development." added Dr. Shawn Zinnen, VP of R&D.

### **About MBC Pharma**

MBC Pharma is a privately held pre-clinical-stage pharmaceutical company developing bone targeted therapeutics for serious diseases and conditions of bone with an oncology focus. MBC Pharma is planning to submit its first IND application in the first quarter of 2010 and subsequently initiate Phase I trials with its first-in-class compound MBC-11.

For information on MBC Pharma please contact Dr. Alexander Karpeisky at 720-859-4041 or Dr. Shawn Zinnen at 720-859-4040

MBC Pharma, Inc.

<http://www.mbcpharma.com>